drug · small molecule
XPOVIO
updated 6mo agoby $KPTI Karyopharm Therapeutics Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 29 investigational indications.
targets
Exportin-1
all catalysts(0)
nothing on the calendar yet
Trials studying XPOVIO
- phase2Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- phase3Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
- phase2A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
- phase2Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
- phase2Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
- phase1Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
- phase3A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- phase2Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
News(6)
- Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raftDebtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with A…biospace · 16d ago
- Karyopharm, deep in debt, to sell itself in bankruptcyThe parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.biopharma_dive · 17d ago
- Karyopharm files Chapter 11, lines up Ayrmid as lead bidder in planned mergerIn an answer to Karyopharm's cash crisis, Irish biotech Ayrmid has agreed to make the first bid on the struggling biopharma's assets in a court supervised auction, teeing up a potential hematology…fiercebiotech · 17d ago
- Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bidGeron has discontinued a phase 3 trial of its Rytelo in JAK inhibitor-pretreated myelofibrosis after an independent data monitoring committee ruled that the study was unlikely to succeed, just as N…fiercebiotech · 22d ago
- Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra useKaryopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…biopharma_dive · 2mo ago
- Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancerKaryopharm’s stock has plummeted after its second attempt to expand its blood cancer medicine Xpovio into endometrial cancer fell short. Late Thursday, the company reported that its latest trial, c…endpoints · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that